Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
WOBURN, Mass. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
WOBURN, Mass. , Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024 . The Company will host a conference call at 8:00
View HTML
Toggle Summary NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
WOBURN, Mass. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic
View HTML
Toggle Summary NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
WOBURN, Mass. , Jan. 08, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in
View HTML
Toggle Summary NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
WOBURN, Mass. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome (PACS), commonly called Long COVID.
View HTML
Toggle Summary NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
WOBURN, Mass. , Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH -funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a
View HTML
Toggle Summary NeuroMetrix Announces One-for-Eight Reverse Stock Split
WOBURN, Mass. , Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the “Effective Time”). The shares underlying the Company's outstanding options will
View HTML
Toggle Summary NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
WOBURN, Mass. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to
View HTML
Toggle Summary NeuroMetrix Reports Q3 2023 Business Highlights
WOBURN, Mass. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
WOBURN, Mass. , Oct. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML